A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 Versus Each of Its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients With Chemotherapy-Refractory Metastatic Colorectal Carcinoma and Acquired Resistance to Anti-EGFR Monoclonal Antibody Therapy
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Futuximab; Modotuximab
- Indications Carcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Symphogen
- 11 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 31 Jan 2019 This trial has been discontinued in Spain.
- 03 Dec 2018 Status changed from recruiting to active, no longer recruiting.